Compton Capital Management Inc. RI trimmed its position in shares of Gilead Sciences (NASDAQ:GILD) by 2.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 60,940 shares of the biopharmaceutical company’s stock after selling 1,420 shares during the period. Gilead Sciences accounts for 1.9% of Compton Capital Management Inc. RI’s investment portfolio, making the stock its 8th biggest holding. Compton Capital Management Inc. RI’s holdings in Gilead Sciences were worth $4,366,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of GILD. BlackRock Inc. boosted its stake in shares of Gilead Sciences by 1.5% during the 4th quarter. BlackRock Inc. now owns 103,797,247 shares of the biopharmaceutical company’s stock valued at $7,436,033,000 after buying an additional 1,552,359 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Gilead Sciences by 1.5% during the 4th quarter. Bank of New York Mellon Corp now owns 30,542,928 shares of the biopharmaceutical company’s stock valued at $2,188,095,000 after buying an additional 446,263 shares during the period. Parnassus Investments CA boosted its stake in shares of Gilead Sciences by 2.5% during the 4th quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock valued at $1,372,604,000 after buying an additional 464,609 shares during the period. Geode Capital Management LLC boosted its stake in shares of Gilead Sciences by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 15,849,063 shares of the biopharmaceutical company’s stock valued at $1,133,346,000 after buying an additional 379,867 shares during the period. Finally, Capital International Investors lifted its stake in shares of Gilead Sciences by 86.6% in the 3rd quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock valued at $908,803,000 after purchasing an additional 5,205,983 shares during the last quarter. Hedge funds and other institutional investors own 78.35% of the company’s stock.
In other news, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $83.51, for a total transaction of $2,087,750.00. Following the transaction, the executive vice president now owns 62,738 shares in the company, valued at approximately $5,239,250.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gayle E. Wilson sold 60,000 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the transaction, the director now owns 182,258 shares in the company, valued at approximately $14,201,543.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 308,600 shares of company stock worth $24,328,226. Insiders own 1.16% of the company’s stock.
Gilead Sciences stock opened at $74.69 on Tuesday. The firm has a market cap of $98,075.59, a price-to-earnings ratio of 8.73, a PEG ratio of -1.73 and a beta of 1.18. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $89.54.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same quarter in the previous year, the business earned $2.70 EPS. The business’s revenue was down 18.7% on a year-over-year basis. equities analysts forecast that Gilead Sciences will post 6.21 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were issued a dividend of $0.57 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, March 15th. This represents a $2.28 annualized dividend and a dividend yield of 3.05%. Gilead Sciences’s payout ratio is presently 26.64%.
Several research firms recently issued reports on GILD. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, April 11th. Barclays reaffirmed an “overweight” rating and issued a $95.00 price objective (up previously from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. BidaskClub lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. Royal Bank of Canada reaffirmed a “buy” rating and issued a $94.00 price objective on shares of Gilead Sciences in a research note on Friday, February 23rd. Finally, Leerink Swann reaffirmed a “market perform” rating and issued a $80.00 price objective (down previously from $83.00) on shares of Gilead Sciences in a research note on Thursday, February 22nd. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $88.61.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/17/gilead-sciences-gild-holdings-trimmed-by-compton-capital-management-inc-ri.html.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.